Indication name: Pulmonary alveolar proteinosis (PAP)
Pulmonary alveolar proteinosis
(PAP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape
Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United
Kingdom, Italy, Japan & China)
Pulmonary Alveolar Proteinosis also
known as pulmonary alveolar lipoproteinosis or phospholipidosis. Pulmonary
alveolar proteinosis (PAP) is a rare disease characterised by alveolar
accumulation of surfactant composed of proteins and lipids due to defective
surfactant clearance by alveolar macrophages.
Classification of Pulmonary
Alveolar Proteinosis:-
Primary PAP (autoimmune PAP,
hereditary PAP)
Secondary PAP (multiple diseases)
Congenital PAP (multiple
diseases, usually genetic)
According to Thelansis
estimates and literature review, autoimmune PAP accounts for 85 – 90 % of all
cases. Hereditary PAP, secondary PAP, and congenital PAP each account for
roughly 5%. Autoimmune PAP occurs in 6-7 people per million individuals in the
general population.
Competitive landscape of
Pulmonary alveolar proteinosis (PAP) includes country specific approved as well
as pipeline therapies. Any asset/ product specific designation or review and
Accelerated Approval are being tracked and supplemented with analyst
commentary.
KOLs insights of Pulmonary
alveolar proteinosis (PAP) across 8 MM market from center of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm and Unmet needs.
Pulmonary alveolar proteinosis
(PAP) Market Forecast: Patient Based Forecast Model (MS.
Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event
and Product Event, Country specific Forecast Model, Market uptake and patient
share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing
scenario, Summary and Insights."
No comments:
Post a Comment